Related Experiment Video
Updated: Jan 3, 2026
Control of Eating Behavior Using a Novel Feedback System
Published on: May 8, 2018
Lisdexamfetamine in Pediatric Binge Eating Disorder: A Retrospective Chart Review
Anna I Guerdjikova1,2, Thomas J Blom2, Nicole Mori1,2
1Lindner Center of HOPE, Mason.
Objectives:
The purpose of this retrospective chart review was to evaluate lisdexamfetamine dimesylate (LDX) in the treatment of pediatric binge eating disorder (BED).
Methods:
We examined the clinical records of 25 patients, 12 to 19 years of age, who were prescribed LDX and had a diagnosis of BED between 2014 and 2017.
Results:
Binge eating disorder in adolescents was highly comorbid with attention deficit hyperactivity disorder, mood and anxiety disorders, and severe obesity. Fifteen participants reported some level of improvement of their BED symptoms with LDX treatment. Posttreatment body mass index (BMI) percentile was not significantly reduced, and all but 2 participants remained in their same BMI classification. Lisdexamfetamine dimesylate treatment duration was not associated with change in BMI percentile, and the medication was well tolerated.
Conclusions:
Lisdexamfetamine dimesylate may have clinical utility for BED in adolescents, but randomized, placebo-controlled studies of its efficacy, tolerability, and safety in this population are needed.
More Related Videos
05:15Author Spotlight: Accessible M&M-Based Mouse Model for Investigating Binge Eating Disorder - Insights into Eating Behaviors, Anxiety, and Neural Mechanisms
Published on: January 10, 2025
04:23A Treatment Package without Escape Extinction to Address Food Selectivity
Published on: August 21, 2015
Related Concept Videos
01:23Binge Eating Disorders
01:30Bulimia Nervosa
01:30Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....